#POLB Poolbeg Pharma PLC – POLB 001 European Patent granted November 20, 2025 – Posted in: Poolbeg Pharma (POLB)

20 November 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome…

#POLB Poolbeg Pharma PLC – Combination of Poolbeg and HOOKIPA Pharma Inc. January 2, 2025 – Posted in: Blog

The boards of directors (each a “Board”) of HOOKIPA Pharma Inc. (“HOOKIPA”) and Poolbeg Pharma plc (“Poolbeg”) are pleased to announce that they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg (the “Potential Combination”) to create a strong clinical-stage biopharmaceutical company focused on developing and commercialising innovative medicines for critical unmet medical needs, with a special focus on next-generation immunotherapies for the treatment of cancer and other serious diseases (the…

#POLB Poolbeg Pharma PLC – Former Amryt Pharma Leadership Team join Poolbeg November 9, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

9 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both Poolbeg and Amryt Pharma plc. Poolbeg intends to follow a similar strategic approach to Amryt…

#POLB Poolbeg Pharma PLC – Interim results for the six months to 30 June 2023 September 13, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

13 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces its unaudited interim results for the six months to 30 June 2023. Interim Results Highlights and Business Update · Strong cash balance of £14.1 million as at 30 June 2023 (31 December 2022: £16.2m) · Positive results from the POLB 001 LPS human challenge trial. The asset has the potential to…

#HVO hVIVO PLC – Positive results from flu human challenge study April 3, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Cidara Therapeutics, Inc. (“Cidara”), reporting positive interim results from an ongoing human challenge study testing CD388. hVIVO is conducting the Phase 2a single-center, randomised, double-blinded, placebo-controlled trial using its H3N2 Influenza Human Challenge Study Model. CD388 is…

#POLB Poolbeg Pharma PLC – Poolbeg identifies novel RSV drug candidates December 21, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus (‘RSV’) artificial intelligence (‘AI’) Programme with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked closely with OneThree to build a tailored AI approach that leverages Poolbeg’s unique RSV human challenge trial data in order to identify disease-relevant biological…

#POLB Poolbeg Pharma Plc- Capital Markets Day November 17, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30 November between 10am – 12:45pm. The event, which will be chaired by Jeremy Skillington, Chief Executive Officer, will provide insights into a number of the Company’s growing pipeline…

#ORPH Open Orphan PLC – Director dealings September 29, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has received notification that on 29 September 2022, Yamin ‘Mo’ Khan, Chief Executive Officer of the Company, purchased 510,204 ordinary shares of 0.1 pence each in the capital of the Company (“Shares”) at a price…

#POLB Poolbeg Pharma – POLB sign AI discovery deal with OneThree Biotech for first human challenge trial March 10, 2022 – Posted in: Poolbeg Pharma (POLB)

POLB’s CEO Jeremy Skillington & One Three Biotech‘s co-founder & COO Brad Pryde catch up with @proactive_UK to discuss the recent AI deal to identify new drugs & treatments for RSV.